2 Paul Tudor Jones II Novartis AG Trades
Paul Tudor Jones II started to build up the position in Novartis AG in Q1 2024. Since then they sold 3.88 Thousand shares. The investor sold all their shares in Q2 2024 and doesn't own any shares in Novartis AG anymore.
News about Novartis AG - ADR and Paul Tudor Jones II
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and...
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc 1 , +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by c...
Novartis phase III data confirm sustained efficacy and long─term safety of oral remibrutinib in chronic spontaneous urticaria
… , and multiple sclerosis4-8. Novartis will submit remibrutinib for approval … effective oral option within the Novartis immunology portfolio, which current...
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.